Dysmenorrhea Treatment Market Research Report- Forecast till 2027

Dysmenorrhea Treatment Market Research Report: By Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), Type of Treatment (Pain Relievers, Hormonal Therapy and Surgery) End User (Hospitals & Clinics, Research Centers and others) and Region (the Americas, Europe, Asia-Pacific and Middle East & Africa)- Forecast till 2027

ID: MRFR/Pharma/0256-HCR | February 2021 | Region: Global | 110 pages

Dysmenorrhea Treatment Market Overview

Dysmenorrhea is commonly known as menstrual cramps, which affect women. When a person experiences dysmenorrhea, she feels throbbing pain in the lower abdomen region. This medical condition is extremely common. Dysmenorrhea can be divided into primary and secondary. Primary dysmenorrhea involves painful and recurring menstrual cramps, whereas secondary dysmenorrhea is characterized by pain that could be due to infection in the reproductive organs of women. It is necessary to seek appropriate treatment so that future health complications can be avoided. Some of the future complications that could arise due to the lack of treatment include fertility issues, the rise in the risk of implantation of a fertilized egg outside the uterus as well as pelvic inflammatory diseases.

Dysmenorrhea Treatment Market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 7,450 Million in 2018 and is projected to register a 12% CAGR over the forecast period.

The high incidence of dysmenorrhea among women from different parts of the globe has boosted the performance of the global dysmenorrhea treatment market. The rise in the level of awareness of severe dysmenorrhea treatment options has influenced the demand in the market. It has been forecasted that the market would show consistent performance during the projected period. The Asia Pacific region is most likely to lead in the global dysmenorrhea treatment market setting due to the existence of major market drivers like initiatives taken by government and non-government agencies. Various market segments are expected to showcase solid performance, which would lead to stability in the dysmenorrhea treatment market size.

A broad range of market players has been working on devising strategies to gain a competitive edge in the dynamic dysmenorrhea treatment industry setting. A comprehensive dysmenorrhea treatment market analysis has been carried out to capture the market drivers, challenges, opportunities, and restraining factors that mold the industry's performance. Furthermore, the impact of the Covid 19 pandemic on the industry has also been critically explored.

Covid-19 Analysis of Dysmenorrhea Treatment Market

The Covid 19 pandemic has taken the shape of a major disrupting element in the dysmenorrhea treatment market setting. It has given rise to numerous barriers for people to seek dysmenorrhea treatment medication for the medical condition. Thus, due to the pandemic, the demand of the industry has been negatively affected to a considerable extent. As women have to abide by strict social distancing norms, they have been facing challenges to seek proper treatment for dysmenorrhea.

Regional Market Summary

Global Dysmenorrhea Treatment Market Share (%), by Region, 2018  Dysmenorrhea Treatment Market

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports

Major Dysmenorrhea Treatment Market Dynamics

Market Drivers

Some of the main drivers that have increased the demand in the dysmenorrhea treatment industry include the high incidence as well as prevalence of the medical condition among women, the better awareness about treatment options that are available in the market, and the rising concerns relating to the severity and complexity of the condition. These drivers have been playing an integral role and strengthening the performance of the dysmenorrhea treatment market at the global level. Based on the dysmenorrhea treatment industry analysis, these drivers would play a major role in influencing the market performance during the forecasted period.


Some of the main challenges that exist in the market include the ongoing pandemic, which makes it difficult for women to seek timely secondary dysmenorrhea treatment and primary dysmenorrhea treatment. Due to the obstacle, the demand of the market has been affected. In addition to this, the evolving dysmenorrhea treatment guidelines also increase the changes in the market, which the market players need to comply with.


There exist numerous opportunities in the dysmenorrhea treatment market that can be exploited in order to positively influence performance at the global level. For instance, the business players operating in the industry need to take into account the latest dysmenorrhea treatment guidelines while devising treatment solutions for vulnerable women. Similarly, the government in diverse geographical regions has the opportunity to extend proper support so that new and innovative primary and secondary dysmenorrhea treatment solutions can be introduced. There is also the opportunity to address the existing side effects of the current drugs and medications.

Restraining factors

A number of factors exist that act as restraints and limit the dysmenorrhea treatment market growth. One of the main factors that have been identified in the dysmenorrhea treatment market research is the traditional family values of females. It would prohibit women from seeking such treatment. Similarly, the high morbidity relating to the medical condition could also adversely decline the demand in the dysmenorrhea treatment industry. In case women would opt for long-term treatment could affect the industry performance and restrain its growth.

Cumulative growth analysis of the market

The dysmenorrhea treatment market research has highlighted that the rising prevalence of dysmenorrhea and increase in awareness of the treatment could accelerate the industry growth during the forecasted period. However, the Covid 19 pandemic could act as a major obstacle and affect the industry's performance. There is scope for the major market layers to comply with the latest dysmenorrhea treatment guidelines while devising suitable treatment solutions.

Dysmenorrhea Treatment Market Segment Overview 

By Type

On the basis of the type, the market can be divided into primary dysmenorrhea and secondary dysmenorrhea treatment solutions. The primary solutions mainly focus on painful and repeated menstrual cramps. The secondary treatment solutions find a solution to deal with the pain which could be caused due to infection in women’s reproductive organs

By Type of Treatment

The global market can be categorized into pain relievers, surgery, and hormonal therapy, based on the type of treatment. The market players have been focusing on diverse approaches so that women can choose the appropriate treatment for dysmenorrhea that is aligned with their health needs and conditions. A common drug available to treat the condition is Glyceryl Trinitrate. The surgery options available for women suffering from dysmenorrhea include Laparoscopy and Hysterectomy.

By End Users

On the basis of the end-users, the global market can be divided into hospitals and clinics, research centers, and others. These treatment solutions are mainly sourced by health care facilities before they reach the final customers, i.e., women who suffer from dysmenorrhea. Based on the severity of the health complexity of female patients, hospitals or clinics combine different treatment solutions such as medication and therapy to the patients.

Dysmenorrhea Treatment Market Regional Analysis

The dysmenorrhea treatment market has a strong presence in different corners of the world. Some of the main regions where the market exists include the Asia Pacific, Americas, Europe and the Middle East, and Africa. Each of these regions plays an integral role in shaping the performance of the market at the global level. The major countries operating in the European market include Germany, France, Italy, and the United Kingdom. In the Americas regional segment, the major countries that influence the global market performance include the United States of America, Canada, and Latin America. The key nations functioning in the Asia Pacific region include Japan, Australia, South Korea, India, and China.

During the forecasted period, the Asia Pacific geographic segment is expected to grow at the fastest rate as compared to other geographical regions. The key factors that would be responsible for its solid market performance include the active participation of government as well as non-government agencies to take initiatives that foster market growth. Similarly, the strengthening of the existing infrastructure in the region is also likely to contribute to the strong performance of the geographical region in the future. The increase in the level of awareness of women relating to available primary and secondary dysmenorrhea treatment options could also play a major role in boosting the performance of the dysmenorrhea treatment market at the global level.

Key Players in the Dysmenorrhea Treatment Market

The key market players that influence the level of performance of the global dysmenorrhea treatment market include:

  • Johnson & Johnson Inc.

  • Pfizer, Inc

  • Sanofi,

  • Bayer AG

  • GlaxoSmithKline

  • Novartis AG

  • Mylan NV

  • Reckitt Benckiser

  • Focus Consumer Healthcare

These market players have been contributing to the dysmenorrhea treatment market growth and increasing the level of competition. During the forecasted period, they could play an influential role in enhancing the market performance.

Recent market developments

  • Companies operating in the global dysmenorrhea treatment market have been looking for dysmenorrhea treatment natural means and thus integrating lifestyle-focused approaches.

  • Innovative technology-based approaches are being devised to extend effective primary dysmenorrhea treatment and secondary dysmenorrhea treatment solutions to vulnerable individuals.

Report Overview

  • A brief overview of the global dysmenorrhea treatment industry

  • Critical analysis of the impact of the Coronavirus pandemic on the market

  • Discussion on diverse market dynamics such as market drivers, challenges, opportunities, and restraining factors

  • Cumulative growth analysis of the global dysmenorrhea treatment industry

  • Overview of main market segments

  • Regional analysis of the market landscape

  • In-depth assessment of the competitive landscape

  • Recent developments in the market setting

Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 7,450 Million
  • 2027: Significant Value
  •   CAGR   12% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Type of Treatment and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Sanofi (France), GlaxoSmithKline (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Focus Consumer Healthcare (US), Johnson & Johnson Inc. (US), Mylan NV (US), Novartis AG (Switzerland), Pfizer, Inc. (US), and Reckitt Benkiser (UK)
      Key Market Opportunities   probable side effects of the drugs
      Key Market Drivers

  • growing prevalence of dysmenorrhea
  • increasing awareness and concern regarding the severity and therapeutics

  • Frequently Asked Questions (FAQ) :

    Dysmenorrhea treatment market valuation was USD 7450 million in 2018.

    Dysmenorrhea treatment market CAGR would be 12% during the forecast period.

    Side-effects of drugs could restrict the dysmenorrhea treatment market growth.

    The types included in the dysmenorrhea treatment market report are primary dysmenorrhea and secondary dysmenorrhea.

    The dysmenorrhea treatment market would be driven by the Americas.

    Sanofi, Johnson & Johnson Inc., Mylan NV, GlaxoSmithKline, Novartis AG, Reckitt Benckiser, Bayer AG, Focus Consumer Healthcare, Pfizer, Inc., and F. Hoffmann-La Roche Ltd are prime players of the global dysmenorrhea treatment market.